Published in BMC Bioinformatics on August 30, 2002
Comparative analysis of the Arabidopsis pollen transcriptome. Plant Physiol (2003) 4.33
Statistical implications of pooling RNA samples for microarray experiments. BMC Bioinformatics (2003) 2.52
Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet (2009) 1.80
Large-scale integration of cancer microarray data identifies a robust common cancer signature. BMC Bioinformatics (2007) 1.74
Expression patterns of a novel AtCHX gene family highlight potential roles in osmotic adjustment and K+ homeostasis in pollen development. Plant Physiol (2004) 1.58
A power law global error model for the identification of differentially expressed genes in microarray data. BMC Bioinformatics (2004) 1.56
Sex-related differences in gene expression in human skeletal muscle. PLoS One (2008) 1.20
Gene Vector Analysis (Geneva): a unified method to detect differentially-regulated gene sets and similar microarray experiments. BMC Bioinformatics (2008) 0.91
Genomic data sampling and its effect on classification performance assessment. BMC Bioinformatics (2003) 0.89
Principal Angle Enrichment Analysis (PAEA): Dimensionally Reduced Multivariate Gene Set Enrichment Analysis Tool. Proceedings (IEEE Int Conf Bioinformatics Biomed) (2015) 0.82
Comparative Meta-Analysis of Transcriptomics Data during Cellular Senescence and In Vivo Tissue Ageing. Oxid Med Cell Longev (2015) 0.78
Toxicity prediction from toxicogenomic data based on class association rule mining. Toxicol Rep (2014) 0.75
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Analyzing high-density oligonucleotide gene expression array data. J Cell Biochem (2000) 16.73
The contributions of sex, genotype and age to transcriptional variance in Drosophila melanogaster. Nat Genet (2001) 8.70
Mitotic misregulation and human aging. Science (2000) 8.47
Gene expression profile of aging and its retardation by caloric restriction. Science (1999) 8.06
Assessment of the relationship between signal intensities and transcript concentration for Affymetrix GeneChip arrays. Genome Biol (2001) 7.01
Gene-expression profile of the ageing brain in mice. Nat Genet (2000) 5.46
Empirical characterization of the expression ratio noise structure in high-density oligonucleotide arrays. Genome Biol (2002) 5.04
Improved statistical inference from DNA microarray data using analysis of variance and a Bayesian statistical framework. Analysis of global gene expression in Escherichia coli K12. J Biol Chem (2001) 4.35
Influences of aging and caloric restriction on the transcriptional profile of skeletal muscle from rhesus monkeys. Proc Natl Acad Sci U S A (2001) 3.63
Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol (2000) 3.34
A systematic statistical linear modeling approach to oligonucleotide array experiments. Math Biosci (2002) 2.53
Computational methods for the identification of differential and coordinated gene expression. Hum Mol Genet (1999) 2.43
Genomic profiling of short- and long-term caloric restriction effects in the liver of aging mice. Proc Natl Acad Sci U S A (2001) 2.28
The effects of aging on gene expression in the hypothalamus and cortex of mice. Proc Natl Acad Sci U S A (2001) 1.72
Match-only integral distribution (MOID) algorithm for high-density oligonucleotide array analysis. BMC Bioinformatics (2002) 1.56
High-abundance mRNAs in human muscle: comparison between young and old. J Appl Physiol (1985) (2000) 1.23
Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism. Neuron (2011) 10.61
Microarray analysis of Pseudomonas aeruginosa quorum-sensing regulons: effects of growth phase and environment. J Bacteriol (2003) 6.36
A muscleblind knockout model for myotonic dystrophy. Science (2003) 5.93
Expanded CUG repeats trigger aberrant splicing of ClC-1 chloride channel pre-mRNA and hyperexcitability of skeletal muscle in myotonic dystrophy. Mol Cell (2002) 4.44
Failure of MBNL1-dependent post-natal splicing transitions in myotonic dystrophy. Hum Mol Genet (2006) 4.35
Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science (2009) 3.62
Myotonic dystrophy type 1 is associated with nuclear foci of mutant RNA, sequestration of muscleblind proteins and deregulated alternative splicing in neurons. Hum Mol Genet (2004) 3.21
Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci U S A (2006) 3.09
Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol (2010) 3.07
Research capacity. Enabling the genomic revolution in Africa. Science (2014) 3.05
Muscleblind-like 1 interacts with RNA hairpins in splicing target and pathogenic RNAs. Nucleic Acids Res (2007) 2.95
The effects of normalization on the correlation structure of microarray data. BMC Bioinformatics (2005) 2.87
Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease. Nat Med (2005) 2.71
Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest (2007) 2.68
Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature (2012) 2.63
Gene expression profile of aging in human muscle. Physiol Genomics (2003) 2.36
Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.32
Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc Natl Acad Sci U S A (2009) 2.21
Rational design of ligands targeting triplet repeating transcripts that cause RNA dominant disease: application to myotonic muscular dystrophy type 1 and spinocerebellar ataxia type 3. J Am Chem Soc (2009) 2.06
Chloride channelopathy in myotonic dystrophy resulting from loss of posttranscriptional regulation for CLCN1. Am J Physiol Cell Physiol (2006) 2.02
Skeletal muscle gene expression profiles in 20-29 year old and 65-71 year old women. Exp Gerontol (2004) 2.00
RNA-dominant diseases. Hum Mol Genet (2006) 2.00
Myotonic dystrophy: RNA-mediated muscle disease. Curr Opin Neurol (2007) 1.91
Muscle chloride channel dysfunction in two mouse models of myotonic dystrophy. J Gen Physiol (2006) 1.83
Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet (2009) 1.80
Sarcolemmal-restricted localization of functional ClC-1 channels in mouse skeletal muscle. J Gen Physiol (2010) 1.73
Dynamic combinatorial selection of molecules capable of inhibiting the (CUG) repeat RNA-MBNL1 interaction in vitro: discovery of lead compounds targeting myotonic dystrophy (DM1). J Am Chem Soc (2008) 1.70
Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol (2007) 1.61
Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet (2003) 1.59
Nuclear RNA foci in the heart in myotonic dystrophy. Circ Res (2005) 1.57
Ribonuclear inclusions in skeletal muscle in myotonic dystrophy types 1 and 2. Ann Neurol (2003) 1.56
Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis (2003) 1.56
Controlling the specificity of modularly assembled small molecules for RNA via ligand module spacing: targeting the RNAs that cause myotonic muscular dystrophy. J Am Chem Soc (2009) 1.54
Copy number variations in 6q14.1 and 5q13.2 are associated with alcohol dependence. Alcohol Clin Exp Res (2012) 1.50
Muscle growth after postdevelopmental myostatin gene knockout. Am J Physiol Endocrinol Metab (2006) 1.49
Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues. Hum Mol Genet (2010) 1.46
Design of a bioactive small molecule that targets the myotonic dystrophy type 1 RNA via an RNA motif-ligand database and chemical similarity searching. J Am Chem Soc (2012) 1.44
Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem Biol (2012) 1.43
Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis. J Neurovirol (2004) 1.38
Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of Ca(V)1.1 calcium channel. Hum Mol Genet (2011) 1.37
Reelin signaling is impaired in autism. Biol Psychiatry (2005) 1.33
A mouse model for study of systemic HIV-1 infection, antiviral immune responses, and neuroinvasiveness. Proc Natl Acad Sci U S A (2005) 1.32
Inhibition of autoregulated TGFbeta signaling simultaneously enhances proliferation and differentiation of kidney epithelium and promotes repair following renal ischemia. Am J Pathol (2009) 1.27
An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum Mol Genet (2002) 1.24
Severity, type, and distribution of myotonic discharges are different in type 1 and type 2 myotonic dystrophy. Muscle Nerve (2007) 1.23
Splicing biomarkers of disease severity in myotonic dystrophy. Ann Neurol (2013) 1.22
Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control (2009) 1.22
Sex-related differences in gene expression in human skeletal muscle. PLoS One (2008) 1.20
Bidirectional transcription stimulates expansion and contraction of expanded (CTG)*(CAG) repeats. Hum Mol Genet (2010) 1.19
Microarray analysis of changes in cellular gene expression induced by productive infection of primary human astrocytes: implications for HAD. J Neuroimmunol (2004) 1.18
Significant effects of antiretroviral therapy on global gene expression in brain tissues of patients with HIV-1-associated neurocognitive disorders. PLoS Pathog (2011) 1.14
Sex differences in the human peripheral blood transcriptome. BMC Genomics (2014) 1.13
Myotonic syndromes. Curr Opin Neurol (2002) 1.11
From dynamic combinatorial 'hit' to lead: in vitro and in vivo activity of compounds targeting the pathogenic RNAs that cause myotonic dystrophy. Nucleic Acids Res (2012) 1.10
Stabilization of expanded (CTG)•(CAG) repeats by antisense oligonucleotides. Mol Ther (2011) 1.10
RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat Genet (2007) 1.09
If you build a rare disease registry, will they enroll and will they use it? Methods and data from the National Registry of Myotonic Dystrophy (DM) and Facioscapulohumeral Muscular Dystrophy (FSHD). Contemp Clin Trials (2011) 1.08
Big results from small samples: evaluation of amplification protocols for gene expression profiling. J Biomol Tech (2007) 1.08
Reduced amount of mitochondrial DNA in aged human muscle. J Appl Physiol (1985) (2002) 1.07
Truncated ClC-1 mRNA in myotonic dystrophy exerts a dominant-negative effect on the Cl current. Neurology (2004) 1.06
Inhibition of neuronal phenotype by PTEN in PC12 cells. Proc Natl Acad Sci U S A (2004) 1.05
Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonic dystrophy (DM1). Muscle Nerve (2007) 1.03
Induction and reversal of myotonic dystrophy type 1 pre-mRNA splicing defects by small molecules. Nat Commun (2013) 1.01
Rational design of bioactive, modularly assembled aminoglycosides targeting the RNA that causes myotonic dystrophy type 1. ACS Chem Biol (2012) 1.01
RNA interference targeting CUG repeats in a mouse model of myotonic dystrophy. Mol Ther (2012) 1.00
Two high-throughput screening assays for aberrant RNA-protein interactions in myotonic dystrophy type 1. Anal Bioanal Chem (2012) 0.99
Diagnostic odyssey of patients with myotonic dystrophy. J Neurol (2013) 0.97
Gene expression profiles of HIV-1-infected glia and brain: toward better understanding of the role of astrocytes in HIV-1-associated neurocognitive disorders. J Neuroimmune Pharmacol (2009) 0.97
A novel role of circadian transcription factor DBP in hippocampal plasticity. Mol Cell Neurosci (2005) 0.97
Reducing levels of toxic RNA with small molecules. ACS Chem Biol (2013) 0.96
Relation between extent of myostatin depletion and muscle growth in mature mice. Am J Physiol Endocrinol Metab (2009) 0.96
Transcriptional profiling of C57 and DBA strains of mice in the absence and presence of morphine. BMC Genomics (2007) 0.95
Early changes in gene expression in two models of Batten disease. FEBS Lett (2003) 0.92
Cell-free cloning of highly expanded CTG repeats by amplification of dimerized expanded repeats. Nucleic Acids Res (2008) 0.92
Copy number variation accuracy in genome-wide association studies. Hum Hered (2011) 0.90
Features of modularly assembled compounds that impart bioactivity against an RNA target. ACS Chem Biol (2013) 0.88
The role of RNA and RNA processing in neurodegeneration. J Neurosci (2005) 0.88
Developmental pesticide exposures and the Parkinson's disease phenotype. Birth Defects Res A Clin Mol Teratol (2005) 0.87
Multiple distinct CHRNB3-CHRNA6 variants are genetic risk factors for nicotine dependence in African Americans and European Americans. Addiction (2014) 0.86
Scaled-down genetic analysis of myotonic dystrophy type 1 and type 2. Neuromuscul Disord (2009) 0.85
Effect of the methoxychlor metabolite HPTE on the rat ovarian granulosa cell transcriptome in vitro. Toxicol Sci (2009) 0.85
Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1. Arch Neurol (2010) 0.85
Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve (2002) 0.84
Identification of restriction endonucleases sensitive to 5-cytosine methylation at non-CpG sites, including expanded (CAG)n/(CTG)n repeats. Epigenetics (2011) 0.82
Glucocorticoid-regulated VEGF expression in ischemic skeletal muscle. Mol Ther (2002) 0.81
Replacement of the myotonic dystrophy type 1 CTG repeat with 'non-CTG repeat' insertions in specific tissues. J Med Genet (2011) 0.79
Prediction of biologically significant components from microarray data: Independently Consistent Expression Discriminator (ICED). Bioinformatics (2003) 0.78
Altered gene expression in the eye of a mouse model for batten disease. Invest Ophthalmol Vis Sci (2004) 0.78
TCDD-induced alterations in gene expression profiles of the developing mouse paw do not influence morphological differentiation of this potential target tissue. Toxicol Sci (2006) 0.78
Progressive myopathy in an inducible mouse model of oculopharyngeal muscular dystrophy. Neurobiol Dis (2011) 0.78
The ABRF MARG microarray survey 2005: taking the pulse of the microarray field. J Biomol Tech (2006) 0.77
Evoked myotonia can be "dialed-up" by increasing stimulus train length in myotonic dystrophy type 1. Muscle Nerve (2010) 0.77
Preparing DNA from blood for genotyping. CSH Protoc (2007) 0.77
Oligonucleotide microarrays reveal regulated genes related to inward arterial remodeling induced by urokinase plasminogen activator. J Vasc Res (2008) 0.76
Long term metabolic arrest and recovery of HEK293 spheroids involves NF-kappaB signaling and sustained JNK activation. J Cell Physiol (2006) 0.76
Molecular fingerprints of inflammatory myopathies. Neurology (2002) 0.75
Correction: Novel Genetic Locus Implicated for HIV-1 Acquisition with Putative Regulatory Links to HIV Replication and Infectivity: A Genome-Wide Association Study. PLoS One (2015) 0.75